The Department of Nuclear Medicine at the Fourth Affiliated Hospital of Zhejiang University School of Medicine was established in 2022. It has now developed a comprehensive nuclear medicine diagnostic and therapeutic system that includes PET/CT, SPECT radionuclide imaging, and radionuclide therapy, and is committed to building a leading specialty in molecular imaging and radionuclide therapy in central Zhejiang.

Nuclear medicine utilizes drugs labeled with trace amounts of radionuclides to diagnose diseases. It primarily reflects local blood flow, function, and metabolism at the site of the lesion, thereby enabling early detection of pathological changes and evaluation of treatment efficacy. It is characterized by being non-invasive, safe, simple to perform, and highly accurate in diagnosis. The field of nuclear medicine holds vast prospects for professional development. Functional imaging at the molecular level and radionuclide-specific targeted therapy are playing an increasingly important role in clinical diagnosis and treatment, serving as one of the hallmarks of high-quality development in precision medicine. The hospital has introduced GE’s most advanced PET/CT imaging system (Discovery Max), which features a unique spiral tomographic acquisition model and algorithms, offering ultra-high sensitivity, resolution, and scanning speed. The department currently routinely performs 18F-FDG PET/CT examinations, including staging of malignant tumors and detection of post-treatment recurrence or metastasis; identification of primary sites for metastatic tumors of unknown origin; and guidance for defining radiation therapy treatment planning regions. The department currently has a staff of 10, including 2 chief physicians, 3 resident physicians, 2 senior nurses, and 3 technologists. The department continuously strengthens its talent development initiatives, broadens training channels, and enhances collaboration with leading domestic hospitals to fully advance the hospital’s disciplinary development. The rapidly evolving field of nuclear medicine holds unique value in the molecular-level diagnosis and treatment of malignant tumors, as well as significant applications across multiple disciplines including endocrinology, cardiology, hematology, and urology. As the department’s technical capabilities and infrastructure continue to improve, it will provide higher-quality services to the people of Yiwu and the Central Zhejiang region.